DOCSLIB.ORG

The First International Conference on Translational Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The First International Conference on Translational Medicine Molecular Psychiatry (2010) 15, 878–879 & 2010 Macmillan Publishers Limited All rights reserved 1359-4184/10 www.nature.com/mp EDITORIAL The First International Conference on Translational Medicine Molecular Psychiatry (2010) 15, 878–879; doi:10.1038/ Table 1 First International Conference on Translational mp.2010.91 Medicine (The 13th Frank and Bobbie Fenner Conference), 1–4 November 2010, John Curtin School of Medical Research, As our mission to foster translational medicine ANU, Canberra, Australia continues to evolve, we have now conceptualized Participant leaders from the USA, Europe, China, and launched a new international conference to cover Singapore and Australia: the transition from discovery to healthcare and global Warwick Anderson, CEO, NHMRC, Australia health. The First International Conference on Transla- Juan Carlos Lopez, Chief Editor, Nature Medicine tional Medicine (the 13th Frank and Bobbie Fenner Anthony Hayward, Director, Clinical and Translational Conference) has a highly innovative mission of Program, NIH, USA bringing together into a global domain what have so Alan Schechter, Chief, Molecular Medicine, NIDDK, far been nationally focused efforts in translational NIH, USA medicine, such as the United States Clinical and Clay Johnston, Director, UCSF Clinical and Translational Translational Science Award (CTSA) mechanism and Science Institute the United Kingdom Academic Health Science Centre Anantha Shekhar, Director, Indiana Translational Institute, USA (AHSC) program. Initiatives from Ireland, which Dame Sally Davies, Director General of Research and created one academic health science center for the Development and Chief Scientific Adviser for the entire country, from China, Singapore and Australia Department of Health and NHS, London, UK will also be discussed and presented (see Table 1). Alastair Buchan, Head, Medical Sciences Division (Dean While carefully thought out and well-funded of Medicine), University of Oxford, UK programs have been developed in many countries to Stephen Smith, Dean of Medicine and CEO, Imperial foster translational medicine, the vast majority of College Healthcare and AHSC those efforts are funded by national taxpayers’ sources Bill Powderly, Dean of Medicine, CEO, Dublin Academic and are therefore restricted for use within each Medical Centre country. What is currently lacking in the world is an Jun Wang, Executive Director, BGI-China Lin He, Director, Bio-X Center, Shanghai Jiao Tong international structure that integrates various national University and Dean, Institutes of Biomedical Sciences, translational efforts, promotes cross-fertilization, Fudan University, Shanghai, China thereby avoiding duplication of effort, and that brings Ranga Krishnan, Dean, Duke-NUS Medical School, the fruits of research to those who are less privileged, Singapore through global health initiatives. By bringing together Alain van Gool, Director, Translational Medicine a very elite group of academic leaders in translational Research Centre, Merck Singapore medicine, we will start an organized process to Eran Leitersdorf, Dean, Faculty of Medicine, Hebrew address these pressing issues. University of Jerusalem, Israel The discussion of whether the outcomes of transla- Sir Gustav Nossal, AC, CBE, FAA, FRS tional research will be restricted to rich, industrial Bruce Singh, Acting Dean, University of Melbourne Steve Wesselingh, Dean of the Faculty of Medicine, and post-industrial countries with an economic basis Monash University to nurture national efforts in translation is of Bruce Robinson, Dean, University of Sydney School considerable importance. That being the case, what of Medicine happens to countries that cannot support such efforts? The premise of translation is to improve Conference website: http://bit.ly/cl0pnZ. health, and if that is being done only in wealthy countries, will translational medicine become a lever to further raise the rich, while the poor stay behind? translational approaches to the diseases that cause so Are we simply expanding the abyss in health out- much morbidity and mortality the world over? comes that exist between disadvantaged nations and Of course, translational medicine is fundamental traditionally (or rapidly emerging) rich countries? If for chronic, non-transmissable illnesses. However, that is not the desired outcome, how can translational the diseases of the rich are to a large degree the medicine be brought to the poor, whose health needs outcome of affluence. If we eliminated overeating, are so profound? How will translational research underspending of calories due to sedentary lifestyles, on neglected tropical diseases or on illnesses that drugs, alcohol and cigarette smoking, health in have long ceased to be public health problems in developed countries would be greatly improved, developed countries be funded? Who will develop without any translational medicine. Editorial 879 Translational strategies that go from bench to fundamental discovery, versus what goes into build- bedside to clinic to health policy are sorely needed ing the infrastructure and pipeline of translation. to address malaria, tuberculosis, leprosy, Chagas and Both are equally needed and healthcare and global diarrheal diseases, among others. The case could be health cannot be improved by one without the made that the public health relevance of those other. diseases would be greatly reduced by improved social These three very hot topics will be approached in a and economic standards. That is true; however, it is moderated discussion or workshop format: not fair to let hundreds of millions die around the How to Create Academic Structures and Partner- world over the coming decades as we sit and wait for ships that Integrate Fundamental Discovery, the quality of life to incrementally rise across the Translational Medicine, Health Care and Global globe. In parallel to promoting better standards of Health. Moderated open discussion led by Robert living, we need to bring translational approaches to Wells (Australian Primary Health Care Research address not only the diseases of the rich, but also the Institute and Menzies Centre for Health Policy, diseases of the poor. Are these efforts the responsi- ANU). bility of international bodies, such as the World Developing a Global Translational Research Work- Health Organization, or are they best funded by force. Workshop led by Michele Pato (University of non-governmental organizations, such as the Bill & Southern California), Monika Ehrhart-Bornstein Melinda Gates Foundation? Should national transla- (University of Dresden, Germany) and Julio Licinio tional programs in the developed countries dedicate a (John Curtin School of Medical Research, ANU). percentage of their budgets to initiatives that are of Where Should the Money Go? To Fundamental more direct benefit to poorer nations? What is the role Discovery or Translation? Moderated open discus- of rapidly emerging countries? sion led by Eran Leitersdorf (Dean, Faculty of These difficult questions will only become more Medicine, Hebrew University of Jerusalem, Israel), pressing over time and will be a major challenge Anthony Hayward (Director, Division of Clinical for the translational research leaders of the future. Research Resources, NCRR, NIH), Warwick Are we effectively developing in sufficient numbers Anderson (CEO, NHMRC), Alastair Buchan (Dean a global workforce in translational medicine? How of Medicine, University of Oxford, UK), and Julio do we train academic leaders who can direct the Licinio (Director, JCSMR, ANU). multidisciplinary translational research teams of the future? They will have to simultaneously under- We invite you and your colleagues to come to stand in depth and navigate the worlds of discovery beautiful Canberra on 1–4 November 2010 to attend and healthcare, survive and thrive tough peer this transformative conference that will for the first review, and will moreover need to acquire extra- time bring into one venue some of the most ordinary skills not only in the multidisciplinary competitive initiatives in translational medicine science and practice of medicine, but also in the worldwide. We also invite you to submit to our poster communication of science, fund raising, manage- session. I am looking forward to welcoming you to ment, advocacy and community engagement. How Australia. can those future leaders be identified, nurtured and transitioned into the right positions at the optimal J Licinio (Editor) time in their careers? John Curtin School of Medical Research, Finally, a very clear-minded dialogue must exist to Australian National University, Canberra, Australia estimate the proportion of funding that goes into E-mail: [email protected] Molecular Psychiatry.
Load more

Recommended publications
  • Schizophrenia: Could It Be Prevented?
    SCHIZOPHRENIA : COULD IT BE PREVENTED ? A SATELLITE MEETING OF THE 2014 ANNUAL MEETING OF THE SOCIETY OF BIOLOGICAL PSYCHIATRY MAY 7, 2014 NEW YORK HILTON MIDTOWN TABLE OF CONTENTS WELCOME MESSAGE 3 ACKNOWLEDGMENTS 4 PROGRAM 5 INTRODUCTION – PROF . MICHEL CUENOD 6 SESSION 1: CHAIRS & SPEAKERS 7 SESSION 2: CHAIRS & SPEAKERS 14 SESSION 3: CHAIRS & SPEAKERS 19 2 WELCOME MESSAGE Early detection of psychotic disorders has recently become a focus for research and clinical development, leading to a major conceptual shift in psychiatry, and to the development of a preventive approach to psychiatric disorders. Based on emerging evidence that treatment delay has a negative impact on outcome, specialized programs to reduce the duration of untreated psychosis and develop specifically adapted treatments have been initiated worldwide. To this effect, it is essential to understand the underlying causes and mechanisms in order to identify key biomarkers profiles, and to develop novel therapeutic and preventive measures based on the etio-pathophysiology. Our Symposium brings together a panel of distinguished leaders in the field, who will present the state of the art of schizophrenia research with focus on pathophysiological mechanisms, genetic and environmental risk factors and their interaction during neurodevelopment. Dialogs between academia and industry on innovative solutions to therapeutic targets will contribute to shape the perspectives on preventive measures. Details regarding the course of the Symposium as well as our speakers and chairs are listed below. We trust that they will meet with your interest, and that we will have an opportunity to share experience, expand our networks, discuss collaborations and cultivate friendships. We thank you for joining us and look forward to a fruitful event.
    [Show full text]
  • Acute Systemic Inflammation Up-Regulates Secretory Sphingomyelinase in Vivo: a Possible Link Between Inflammatory Cytokines and Atherogenesis
    Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis Ma-Li Wong*, Boxun Xie†, Nan Beatini†, Phan Phu‡, Sudhir Marathe†, Anthony Johns§, Philip W. Gold‡, Emmet Hirsch¶, Kevin Jon Williamsʈ, Julio Licinio*, and Ira Tabas†** *Department of Psychiatry and Biobehavioral Sciences, University of California, School of Medicine, Los Angeles, CA 90095-1761; Departments of †Medicine, Anatomy, and Cell Biology and ¶Obstetrics and Gynecology, Columbia University, New York, NY 10032; ‡Clinical Neuroendocrinology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1284; §Berlex Biosciences, Richmond, CA 94804; and ʈDorrance H. Hamilton Research Laboratories, Division of Endocrinology, Diabetes, and Metabolic Diseases, Thomas Jefferson University, Philadelphia, PA 19107 Edited by S. M. McCann, Pennington Biomedical Research Center, Baton Rouge, LA, and approved May 23, 2000 (received for review March 7, 2000) Inflammation plays a critical role in atherogenesis, yet the medi- sphingomyelinase (SMase) (20, 21). Ceramide generated from ators linking inflammation to specific atherogenic processes re- SMase activation has been reported to play roles in cytokine- main to be elucidated. One such mediator may be secretory mediated apoptosis, cellular differentiation, and cellular senes- sphingomyelinase (S-SMase), a product of the acid sphingomyeli- cence (20, 21), each of which may be important in the inflam- nase gene. The secretion of S-SMase by cultured endothelial cells matory response. Whereas studies in vitro have suggested roles is induced by inflammatory cytokines, and in vivo data have for several different mammalian SMase activities in various implicated S-SMase in subendothelial lipoprotein aggregation, ceramide signaling pathways (20, 21), a product of the acid macrophage foam cell formation, and possibly other atherogenic SMase (ASM) gene has been implicated in several specific processes.
    [Show full text]
  • Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma
    Molecular Neurobiology https://doi.org/10.1007/s12035-018-1359-3 Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma Antonio Inserra1,2,3 & Claudio Alberto Mastronardi4,5 & Geraint Rogers6,7 & Julio Licinio8,9 & Ma-Li Wong1,2,9 Received: 29 April 2018 /Accepted: 19 September 2018 # The Author(s) 2018 Abstract Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and its incidence is expected to increase. Despite tremendous efforts to understand its underlying biological mechanisms, MDD pathophysiology remains elusive and pharmacotherapy outcomes are still far from ideal. Low-grade chronic inflammation seems to play a key role in mediating the interface between psychological stress, depressive symptomatology, altered intestinal microbiology, and MDD onset. We review the available pre-clinical and clinical evidence of an involvement of pro-inflammatory pathways in the pathogenesis, treatment, and remission of MDD. We focus on caspase 1, inducible nitric oxide synthase, and interferon gamma, three inflammatory systems dysregulated in MDD. Treatment strategies aiming at targeting such pathways alone or in combination with classical therapies could prove valuable in MDD. Further studies are needed to assess the safety and efficacy of immune modulation in MDD and other psychiatric disorders with neuroinflammatory components. Keywords Major depressive disorder . MDD . Inflammation . Neuroinflammation . Caspase 1 . Inflammasome . T-helper 1 (Th1) . Interleukin 1 . Inducible nitric oxide synthase . Interferon gamma . Gut microbiome Introduction describe the elusive pathophysiology of MDD, including the monoamine hypothesis, the neurotrophic hypothesis, the gluta- Major depressive disorder (MDD) is a psychiatric disorder with mate hypothesis, the cytokine (or macrophage) hypothesis, and significant morbidity, mortality, disability, and economic bur- the microbiota-inflammasome hypothesis [8–13].
    [Show full text]
  • 2014 ADA Posters 1319-2206.Indd
    INTEGRATED PHYSIOLOGY—INSULINCATEGORY SECRETION IN VIVO 1738-P increase in tumor size and pulmonary metastasis is observed, compared Sustained Action of Ceramide on Insulin Signaling in Muscle Cells: to wild type mice. In this study, we aimed to determine the mechanisms Implication of the Double-Stranded RNA Activated Protein Kinase through which hyperinsulinemia and the canonical IR signaling pathway drive RIMA HAGE HASSAN, ISABELLE HAINAULT, AGNIESZKA BLACHNIO-ZABIELSKA, tumor growth and metastasis. 100,000 MVT-1 (c-myc/vegf overexpressing) RANA MAHFOUZ, OLIVIER BOURRON, PASCAL FERRÉ, FABIENNE FOUFELLE, ERIC cells were injected orthotopically into 8-10 week old MKR mice. MKR mice HAJDUCH, Paris, France, Białystok, Poland developed signifi cantly larger MVT-1 (353.29±44mm3) tumor volumes than Intramyocellular accumulation of fatty acid derivatives like ceramide plays control mice (183.21±47mm3), p<0.05 with more numerous pulmonary a crucial role in altering the insulin message. If short-term action of ceramide metastases. Western blot and immunofl uorescent staining of primary tumors inhibits the protein kinase B (PKB/Akt), long-term action of ceramide on insulin showed an increase in vimentin, an intermediate fi lament, typically expressed signaling is less documented. Short-term treatment of either the C2C12 cell in cells of mesenchymal origin, and c-myc, a known transcription factor. Both line or human myotubes with palmitate (ceramide precursor, 16h) or directly vimentin and c-myc are associated with cancer metastasis. To assess if insulin with ceramide (2h) induces a loss of the insulin signal through the inhibition and IR signaling directly affects the expression these markers, in vitro studies of PKB/Akt.
    [Show full text]
  • LEPTIN ENDOCRINE UPDATES Shlomo Melmed, M.D., Series Editor
    LEPTIN ENDOCRINE UPDATES Shlomo Melmed, M.D., Series Editor J.A. Fagin (ed.): Thyroid Cancer. 1998. ISBN: 0-7923-8326-5 J.S. Adams and B.P. Lukert (eds.): Osteoporosis: Genetics, Prevention and Treatment. 1998. ISBN: 0-7923-8366-4. B.-A. Bengtsson (ed.): Growth Hormone. 1999. ISBN: 0-7923-8478-4 C. Wang (ed.): Male Reproductive Function. 1999. ISBN: 0-7923-8520-9 B. Rapoport and S.M. McLachlan (eds.): Graves' Disease: Pathogenesis and Treatment. 2000. ISBN: 0-7923-7790-7. W. W. de Herder (ed.): Functional and Morphological Imaging of the Endocrine System. 2000. ISBN 0-7923-7923-9 H.G. Burger (ed.): Sex Hormone Replacement Therapy. 2001. ISBN 0-7923-7965-9 A. Giustina (ed.): Growth Hormone and the Heart. 2001. ISBN 0-7923-7212-3 W.L. Lowe, Jr. (ed.): Genetics of Diabetes Mellitus. 2001. ISBN 0-7923-7252-2 J.F. Habener and M.A. Hussain (eds.): Molecular Basis of Pancreas Development and Function. 2001. ISBN 0-7923-7271-9 N. Horseman (ed.): Prolactin. 2001. ISBN 0-7923-7290-5 M. Castro (ed.): Transgenic Models in Endocrinology. 2001 ISBN 0-7923-7344-8 R. Bahn (ed.): Thyroid Eye Disease. 2001. ISBN 0-7923-7380-4 M.D. Bronstein (ed.): Pituitary Tumors in Pregnancy ISBN 0-7923-7442-8 K. Sandberg and S.E. Mulroney (eds.): RNA Binding Proteins: New Concepts in Gene Regulation. 2001. ISBN 0-7923-7612-9 V. Goffin and P. A. Kelly (eds.): Hormone Signaling. 2002 ISBN 0-7923-7660-9 M. C. Sheppard and P. M. Stewart (eds.): Pituitary Disease. 2002 ISBN 1-4020-7122-1 N.
    [Show full text]
  • The Difference You Make
    THE DIFFERENCE YOU MAKE ANNUAL REPORT 2018–2019 TIME, TALENT, AND TREASURE This annual report affords me the chance to reflect on theT school’shis annual accomplishments report affords me over the chancethe past to yearreflect Center, and the Tata Innovation Center — that serve as withon thepride school’s and gratitude. accomplishments I am struck over by the what past we’ve year Johnson’s collective home. beenwith able pride to and achieve gratitude. together, I am stranduck so by grateful what we’ve Also in the vein of bringing people together, the forbeen the able community to achieve that together has built, and our so legacy grateful and for the Tata Innovation Center on Roosevelt Island now hosts continuescommunity to thatsupport has builtour ongoing our legacy growth. and continues numerous key Johnson programs: our Executive MBA/ to support our ongoing growth. MS in Healthcare Leadership, the Executive MBA Metro You are that community, and you are the reason NY, and, of course, the Cornell Tech MBA, as well as for Johnson’s success. supporting half-semester intensives and weekend As we all know, the people who make up courses that bring our Ithaca-based students to study Johnson are bright, driven, and accomplished, but what’s truly at the Cornell Tech campus. These significant developments help exceptional is their engagement and dedication. Members of the tie together different programs and student communities, allowing Johnson community have given so much of themselves to help students in executive MBA and residential MBA programs to work realize our success, and their ongoing dedication is inspiring.
    [Show full text]
  • U.S. Department of Health and Human Services
    U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY Eighth Meeting Friday, October 20, 2005 Brookside Room A/B Marriott Bethesda North Hotel and Montgomery County Conference Center 5701 Marinelli Road North Bethesda, Maryland IN ATTENDANCE: Acting Chair Cynthia E. Berry, J.D. Partner Powell Goldstein LLP 901 New York Avenue, N.W., 3rd Floor Washington, D.C. 20001 Members Sylvia Mann Au, M.S., C.G.C. State Genetics Coordinator Hawaii Department of Health Genetics Program 741 Sunset Avenue Honolulu, HI 96816 Chira Chen Staff Research Associate Comprehensive Cancer Center University of California, San Francisco 2340 Sutter Street, Suite N171 San Francisco, CA 94115 James P. Evans, M.D., Ph.D. Director of Clinical Genetics and the Bryson Program in Human Genetics University of North Carolina, Chapel Hill Medical Bioinformatics Research Building, Suite 4200 CB# 7264 103 Mason Farm Road Chapel Hill, NC 27599-7624 Kevin T. FitzGerald, S.J., Ph.D. Dr. David P. Lauler Chair in Catholic Health Care Ethics Research Associate Professor Department of Oncology Georgetown University Medical Center Building D, Suite 236 4000 Reservoir Road, N.W. Washington, D.C. 20057 IN ATTENDANCE: Julio Licinio, M.D. Professor of Psychiatry and Medicine/Endocrinology Neuropsychiatric Institute David Geffen School of Medicine at UCLA University of California, Los Angeles Gonda Center, Room 3357A 695 Charles Young Drive South Los Angeles, CA 90095-1761 Agnes Masny, R.N., M.P.H., M.S.N. Adjunct Assistant Professor of Nursing Temple University College of Allied Health Professionals Research Assistant and Nurse Practitioner Family Risk Assessment Program Fox Chase Cancer Center Prevention Pavilion 7701 Burholme Avenue Philadelphia, PA 19111 Joseph Telfair, Dr.P.H., M.S.W., M.P.H.
    [Show full text]
  • Acetyl-L-Carnitine Deficiency in Patients with Major Depressive Disorder
    Acetyl-L-carnitine deficiency in patients with major SEE COMMENTARY depressive disorder Carla Nascaa,1, Benedetta Bigioa,b, Francis S. Leec,d, Sarah P. Younge,f, Marin M. Kautzg, Ashly Albrightd, James Beasleyf, David S. Millingtone,f, Aleksander A. Mathéh, James H. Kocsisd, James W. Murroughg, Bruce S. McEwena,1, and Natalie Rasgona,i aHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065; bBiostatistics and Experimental Research Design, Center for Clinical and Translational Science, The Rockefeller University, New York, NY 10065; cSackler Institute for Developmental Psychobiology, Weill Cornell Medical College, New York, NY 10065; dDepartment of Psychiatry, Weill Cornell Medical College, New York, NY 10065; eDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710; fBiochemical Genetics Laboratory, Duke University Health System, Durham, NC 27710; gMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029; hDepartment of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden; and iCenter for Neuroscience in Women’s Health, Stanford University, Palo Alto, CA 94305 Contributed by Bruce S. McEwen, June 15, 2018 (sent for review February 2, 2018; reviewed by Julio Licinio, Robert M. Post, and Charles L. Raison) The lack of biomarkers to identify target populations greatly limits neurotrophic factor (BDNF) and a critical regulator of synaptic the promise of precision medicine for major depressive disorder glutamate release, the metabotropic glutamate receptor of class-2, (MDD), a primary cause of ill health and disability. The endoge- mGlu2 (10, 16–18). In several animal models, LAC supplementa- nously produced molecule acetyl-L-carnitine (LAC) is critical for hip- tion has been shown to ameliorate glutamatergic dysfunction and pocampal function and several behavioral domains.
    [Show full text]
  • Annual Meeting
    2018 Annual Meeting Preliminary Program and Registration Information Join the conversation: #APAAM18 psychiatry.org/annualmeeting ANNUAL MEETING May 5-9, 2018 • New York City 2 Table of Contents Building Well-Being Through Innovation 3 Frequently Asked Questions 39 Schedule-at-a-Glance 5 Getting to New York 45 General Information 7 Hotel Reservation Information 50 Program Format Descriptions 11 Hotel Descriptions 51 Learning Labs 14 Hotel Listings and Amenities 55 Master Course Listings 18 Hotel Map 57 Course Listings 20 Shuttle Bus Routes 58 Scientific Program Lecturers 35 Registration Information 59 APA Administration Meetings and Conventions Scientific Program Committee Consultants CEO and Medical Cathy L. Nash, CMP Linda L. M. Worley, M.D. Josepha Cheong, M.D. Director's Office Director Chairperson David F. Gitlin, M.D. Jacqueline Feldman, M.D. Saul Levin, M.D., M.P.A. Vernetta Copeland Margo Lauterbach, M.D. Iqbal Ahmed, M.D. Chief Executive Officer and Associate Director Susan V. McLeer, M.D. Medical Director Vice-Chairpersons Stephanie Dumey, CMP Sarah Oreck, M.D., M.S. Associate Director Division of Education APA President Eric R. Williams, M.D. Tristan Gorrindo, M.D. Chantalle Hinton Anita Everett, M.D. Corresponding Members Deputy Medical Director Associate Director Members Alvaro Camacho, M.D. Director, Education Division Traci Williams Lara J. Cox, M.D. J. Raymond DePaulo, M.D. Nina Taylor, M.A. Senior Meeting Planner Nancy Diazgranados, M.D. Maria I. Lapid, M.D. Deputy Director, Education Jamie Woodside, CEM Anna L. Dickerman, M.D. Division Exhibits & Meetings Manager Julio Licinio, M.D. Donald C. Goff, M.D.
    [Show full text]
  • Mind and Brain Theme Student Opportunities
    Mind and Brain Theme Student Opportunities Project 1: Chronic fatigue syndrome: Leptin, interleukin 6 and clinical symptoms Supervisors: Professor Julio Licinio, Dr Michael Musker Student: Honours Chronic fatigue syndrome (CFS) is characterised by a constellation of symptoms in previously healthy and active individuals. Because of these symptoms, quality of life of persons with CFS can be extremely compromised. While the search for a clear-cut cause remains elusive, we believe that we can make a major contribution to patient’s quality of life by elucidating the biological basis of their clinical symptoms. If the proximal biology underlying the disabling symptoms of CFS is elucidated, we will be able to target treatments aimed at symptomatic improvement. This project will involve assisting the research team in setting up human research study, interviewing participants, sampling and storage processes for bloods, collecting data from human participants in a mental health context, data collation and analysis. Mind & Brain: Laboratory Research The laboratory research group addresses the mechanisms of mind & brain disorders utilising molecular techniques and models in a laboratory environment. Project 2: The role of stress in cancer initiation and progression Supervisors: Professor Julio Licinio, Dr Martin Lewis, Mr Rhys Fogarty Student: Honours There is growing evidence that chronic psychosocial stress contributes to cancer initiation and progression, however the molecular mechanisms underlying this phenomenon are poorly understood. Chronic exposure of cells to hormones released during stress may activate pro- malignant pathways that increase the cell’s susceptibility to carcinogens and enhance malignant characteristics. The aim of this work is to use an in vitro model of chronic stress involving long-term exposure of cancer and normal cell lines to stress hormones.
    [Show full text]
  • Depression and Obesity Treatments Are Life Saving
    LETTERS TO THE EDITOR Depression and obesity treatments are life saving To the editor—I was disappointed to read United States3. When causes of death are University of California, Los Angeles in your September 2002 issue a classifica- examined by age group, the importance Los Angeles, California, USA tion of antidepressants and antiobesity of suicide as a cause of death is self-evi- Email: [email protected] drugs as “lifestyle drugs”1. Depression is dent (Table 1)3. Moreover, depression is not a lifestyle; it is a severe medical disor- an independent risk factor for heart dis- We reply—We certainly agree that depres- der that has been recognized as such ease, which is the leading cause of mor- sion and obesity are potentially life-threat- 2 since antiquity . Melancholia (black bile tality in the US. In this context, ening conditions, and regret the in Greek) is a subtype of depression that antidepressant treatment is not a characterization of these in our news story was named by Hippocrates 2,500 years lifestyle option, it is a life-saving neces- as mere “lifestyles”. However, we stand by ago. It is the only disease category to sity. the main part of the piece, which focused have survived in its original name from Obesity is also a key contributor to not only on these conditions, but on other the Hippocratic classification of disease morbidity and mortality and can have a afflictions currently the focus of pharma- 2 based on the four humors . Moreover, profound negative impact on health and ceutical development, including hair loss, people die of depression, and do so in life expectancy.
    [Show full text]
  • Chadi Abdallah, M.D. Associate Member Baylor College of Medicine
    Chadi Abdallah, M.D. Ted Abel, Ph.D. James Abelson, M.D.,Ph.D. Associate Member Fellow Member Emeritus Baylor College of Medicine University of Iowa, Carver College of University of Michigan Health System Medicine Anissa Abi-Dargham, M.D. Megumi Adachi, Ph.D. R. Alison Adcock, M.D.,Ph.D. Fellow Associate Member Associate Member Stony Brook University Astellas Research Institute of America Duke University LLC Nii Addy, Ph.D. Nika Adham, B.Sc.,M.Sc.,Ph.D. Bryon Adinoff, M.D. Associate Member Member Fellow Emeritus Yale University School of Medicine Abbvie University of Colorado Medical School Caleb Adler, M.D. Martin Adler, Ph.D. George Aghajanian, M.D. Member Fellow Emeritus Fellow Emeritus University of Cincinnati College of Temple University School of Medicine Yale University School of Medicine Medicine Bernard Agranoff, B.S.,M.D. Susanne Ahmari, M.D.,Ph.D. Katherine Aitchison, Fellow Emeritus Member B.A.,FRCPsych,Ph.D. University of Michigan University of Pittsburgh Member University of Alberta Howard Aizenstein, M.D.,Ph.D. Olusola Ajilore, M.D.,Ph.D. Schahram Akbarian, M.D.,Ph.D. Member Member Member University of Pittsburgh University of Illinois at Chicago Icahn School of Medicine At Mount Sinai Huda Akil, Ph.D. Martin Alda, FRCPC,M.D. Robert Alexander, M.D. Fellow Member Member University of Michigan Dalhousie University Takeda George Alexopoulos, M.D. Tanya Alim, M.D. Murray Alpert, Ph.D. Fellow Emeritus Member Fellow Emeritus Weill Cornell Medical College Howard University Larry Alphs, M.D.,Ph.D. C. Anthony Altar, Ph.D. Susan Amara, Ph.D.
    [Show full text]